NDA 218347 · Abbvie
Rinvoq Lq
Upadacitinib · Oral · Janus Kinase Inhibitor
OrphanLast checked: Nov 19, 2026Latest source record: Jun 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Apr 26, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
112
53 Phase 3, 36 recruiting
FAERS reports
85,284
58,460 serious, 3,196 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS SERIOUS INFECTIONS Patients treated with RINVOQ /RINVOQ LQ are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 ), Adverse Reactions ( 6.1 )]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt RINVOQ /RINVOQ LQ until the infection is controlled. Reported infections include: Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before RINVOQ /RINVOQ LQ use and during therapy. Treatment for latent infection should be considered prior to RINVOQ /RINVOQ LQ use. Invasive fungal infections, including cryptococcosis...
What it is approved for
From the label in effect Jun 30, 2026.
RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for UC, or...
Mechanism: Upadacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs) which modulate intracellular activity including gene expression. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- RINVOQ LQ · UPADACITINIB 1MG/ML · SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Upadacitinib" as an intervention, any sponsor and status, largest first.
AbbVieAbbVie (ABBV)
NCT03104400 · 1,705 participants · Start Apr 27, 2017 · Primary completion Sep 26, 2019
Drug: Adalimumab; Upadacitinib and 2 more · For: Psoriatic Arthritis
Sites: Huntsville, Alabama; Peoria, Arizona; Phoenix, Arizona · 345 sites in all
- A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to MethotrexatePivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT02629159 · 1,629 participants · Start Dec 1, 2015 · Primary completion Oct 27, 2017
Drug: Placebo for Adalimumab; Adalimumab and 2 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Mesa, Arizona; Peoria, Arizona · 370 sites in all
- A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT03568318 · 1,533 participants · Start Aug 9, 2018 · Primary completion Feb 16, 2021
Drug: Placebo; Upadacitinib and 1 more · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 193 sites in all
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06012240 · 1,500 participants (planned) · Start Oct 11, 2023 · Primary completion Apr 2030
Drug: Upadacitinib; Placebo · For: Alopecia Areata
Sites: Birmingham, Alabama; Glendale, Arizona; Phoenix, Arizona · 272 sites in all
- A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT05889182 · 1,328 participants (planned) · Start Jun 21, 2023 · Primary completion Aug 2028
Drug: Upadacitinib; Placebo · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Fountain Hills, Arizona; Phoenix, Arizona · 285 sites in all
- A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)Pivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT02819635 · 1,302 participants · Start Sep 26, 2016 · Primary completion Dec 13, 2021
Drug: Placebo; Upadacitinib · For: Ulcerative Colitis (UC)
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 496 sites in all
- Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus ErythematosusPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT05843643 · 1,014 participants · Start Jul 25, 2023 · Primary completion Mar 2027
Drug: Upadacitinib; Placebo · For: Systemic Lupus Erythematosus
Sites: Chandler, Arizona; Flagstaff, Arizona; Gilbert, Arizona · 369 sites in all
- A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken MethotrexatePivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT02706873 · 1,002 participants · Start Feb 23, 2016 · Primary completion Mar 15, 2018
Drug: Placebo to Upadacitinib; Methotrexate and 2 more · For: Rheumatoid Arthritis
Sites: La Mesa, California; Palm Desert, California; Daytona Beach, Florida · 290 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pain5,607
- arthralgia5,049
- drug ineffective4,961
- rheumatoid arthritis3,494
- covid-193,238
- pain in extremity2,951
- fatigue2,855
- surgery2,719
- fall2,624
- headache2,052
- pneumonia2,046
- death2,040
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 7 |
| 2019 | 221 |
| 2020 | 2,841 |
| 2021 | 5,924 |
| 2022 | 16,500 |
| 2023 | 15,076 |
| 2024 | 15,234 |
| 2025 | 17,249 |
| 2026 | 12,226 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rinvoq Lq (Upadacitinib)
2024 spending
$479K
Beneficiaries
15
40 claims
Per beneficiary
$31,925
$16.52 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $478,881 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.
Loftus EV, Panés J, Lacerda AP, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.
Blockmans D, Penn SK, Setty AR, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update.
Drucker AM, Lam M, Prieto-Merino D, et al. · JAMA Dermatol 2024 · Systematic Review, Network Meta-Analysis
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Blauvelt A, Teixeira HD, Simpson EL, et al. · JAMA Dermatol 2021 · Clinical Trial, Phase III, Multicenter Study
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu AWL, Wong MM, Rayner DG, et al. · J Allergy Clin Immunol 2023 · Systematic Review, Network Meta-Analysis
- Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis.
Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology 2024 · Systematic Review, Comparative Study
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.